你即將離開本站

並前往https://www.biopharma-reporter.com/Article/2021/12/20/Novartis-exits-Mesoblast-COVID-treatment-deal

Novartis exits Mesoblast COVID treatment deal - BioPharma ...

20-Dec-2021 - Last updated on 20-Dec-2021 at 08:32 GMT ... explored as a potential treatment for acute respiratory distress syndrome (ARDS) due to COVID-19.

確定！ 回上一頁

查詢 「ARDS guideline 2021」的人也找了：